Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Hepatology (Baltimore, Md.)|May 27, 2006
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionRichard K Sterling, Eduardo Lissen, Nathan Clumeck, et al.
Antiviral Therapy|February 22, 2007
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trialZoe Fox, Ulrik B Dragsted, Jan Gerstoft, et al.
Antiviral Therapy|May 15, 2002
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapyMounir Ait-Khaled, Abdelrahim Rakik, Philip Griffin, et al.
The Journal of Infectious Diseases|August 23, 2003
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 TrialUlrik Bak Dragsted, Jan Gerstoft, Court Pedersen, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
EMBO Molecular Medicine|December 19, 2015
Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1Sophie Bouchat, Nadège Delacourt, Anna Kula, et al.
AIDS (London, England)|July 17, 2007
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infectionGregory J Dore, Francesca J Torriani, Maribel Rodriguez-Torres, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 ResultsDavid Wohl, Shinichi Oka, Nathan Clumeck, et al.
The New England Journal of Medicine|October 4, 2008
Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick, Jacob Lalezari, James Goodrich, et al.
The Lancet. Infectious Diseases|December 5, 2016
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort studyJohn Gregson, Pontiano Kaleebu, Vincent C Marconi, et al.
Pageof 7